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Abstract
RanBPM is an evolutionarily conserved multi-domain protein that has been implicated in
the regulation of several cellular process including protein stability, cell migration, gene
transcription, and apoptosis. RanBPM is identified as a key member of the CTLH
complex, an orthologous complex to a yeast E3 ubiquitin ligase complex, the exact
function of which remains unknown. Previously, our laboratory identified RanBPM as an
inhibitor of the ERK1/2 pathway through the modulation of C-RAF protein levels. This
study shows that RanBPM-mediated degradation of C-RAF occurs through the
proteasome and the entire CRA domain of RanBPM is necessary for direct interaction
with C-RAF and for effective downregulation of C-RAF in human cells. Finally, the
CTLH complex member RMND5A regulates endogenous C-RAF protein levels further
implicating the CTLH complex in RanBPM-mediated regulation of C-RAF stability. This
study provides further insight into the function of RanBPM and the CTLH complex, and
their regulation of C-RAF.

Keywords
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Chapter 1

1

Introduction

1.1

Cancer

Following several decades of rapid advancements in the scientific field, cancer research
has developed significantly. With cancer as the leading cause of death in Canadian
citizens (1), a wealth of knowledge has been gathered and has revealed cancer to be a
complex disease involving many changing factors. As of 2017, Canadian Cancer
Statistics estimates that 1 in 2 Canadians will develop cancer in their lifetime, and 1 in 4
will die from the disease (1). Therefore, uncovering the complexities of this disease and
discovering new avenues for prevention and treatment are imperative to our health and
longevity.
Numerous studies indicate that cancer pathogenesis is a multistep process that requires
various genetic modifications to occur to cause the progression of a normal human cell,
which is strictly monitored during growth, replication, and death, into a malignant body
that loses these regulations. These lost regulations can be categorized into ten hallmarks,
these being evasion of growth suppression, sustained proliferative signals, resistance to
cell death, sustained angiogenesis, replicative immortality, activation of metastasis,
deregulation of cellular energetics, avoiding immune destruction, inflammation, and
genomic instability (2).
Understanding the underlying molecular mechanisms leading to malignancy can provide
the necessary information to develop new strategies for treatment or possibly even its
prevention. This study investigates the role of Ran-binding protein in the microtubule
organizing center (RanBPM) in the inhibition of the extracellular signal-regulated kinase
(ERK) 1/2 pathway, a pathway commonly found to be deregulated in cancers, through its
regulation of rapidly accelerating fibrosarcoma (C-RAF) protein stability.
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1.2
1.2.1

RanBPM
General overview

RanBPM, also referred to as RanBP9, was the ninth Ran binding partner to be identified
by yeast two-hybrid method in search of Ran binding proteins (3). It was first identified
as a 55 kDa protein that interacts with Ran, however RanBPM did not contain the
consensus Ran-binding domain (3), and was later shown to have no interaction with Ran
in vivo (4). RanBPM is a ubiquitously expressed, non-enzymatic protein with nuclear and
cytoplasmic localization owing to its two nuclear localizing signals and one nuclear
export signal (5). RanBPM has also been identified as an evolutionarily conserved
protein which shares close homology to a wide variety of species, including lower
eukaryotes, plants, and fungi (6).
The initial findings of RanBPM being a 55 kDa protein were later dismissed, as the full
length form of RanBPM was found to be a 90 kDa protein. Additionally, the full length
RanBPM was recovered by gel filtration methods in a large protein complex of 670 kDa
(4). RanBPM has since been implicated in several cellular processes including cellular
growth, migration and adhesion, as well as the regulation of gene transcription and
apoptosis (7-15). Several studies have identified an array of proteins that interact with
RanBPM, which leads most to believe RanBPM to be a scaffold protein (16).

1.2.2

Conserved domains and structure

RanBPM contains several conserved domains, each with the potential to provide a
protein-protein interaction site (Figure 1.1). RanBPM consists of five domains, the Nterminal proline/glutamine rich domain, the spore lysis A and ryanodine receptor domain
(SPRY), the lissencephaly type-1-like homology (LisH) domain, the C-terminal to LisH
(CTLH) domain, and the C-terminal CT11-RanBPM (CRA) domain (3, 4, 17, 18). The
N-terminal is a highly disordered, proline and glutamine rich domain (4) containing six
predicted Src homology 3 (SH3)-binding domains (19). The SPRY domain is a conserved
structural domain that mediates protein-protein interactions (18, 20). This domain was
first identified in Dictyostelium discoideum dual specificity kinase spore lysis A (SplA)
and ryanodine receptors (21), and has been since shown to be a domain present in many
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Figure 1.1 Schematic diagram of full-length RanBPM. Conserved domains are shown:
the SPRY (spore lysis A and ryanodine receptor) domain; the LisH (lissencephaly type-1like homology) domain; the CTLH (C-terminal to the LisH) domain; and the CRA
(CT11-RanBPM) domain. Figure adapted from (16).
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proteins in higher eukaryotes. Little information is known of the role and function this
domain plays in many proteins, however it is interesting to note that the majority of
SPRY domain containing proteins also possess a RING (really interesting new gene) –
type zinc-finger domain (20), and over one-third of proteins with both a SPRY and RING
domain that were investigated exhibit E3 ubiquitin ligase activity (22). Recently, the
crystal structure of the RanBPM SPRY domain was elucidated, it being the only one of
the four conserved domains with its structure solved. The RanBPM SPRY domain forms
a b-sandwich fold that consists of two seven-stranded anti-parallel b-sheets with two ahelices, one at each terminal (23). C-terminal to the SPRY domain are the LisH and
CTLH domains. Together, these two domains have been shown to contribute to the
regulation of microtubule dynamics (17) and to mediate dimerization and oligomerization
(24-26). Lastly, the C-terminal CRA domain has been identified as a novel proteinprotein interaction domain containing a predicted six a-helices reminiscent of the death
domain superfamily (18).
Since its discovery, RanBPM has been shown to associate with several proteins through
its interaction domains. To date, there are over 75 protein interactions that have been
documented, with many of these interactions resulting in an alteration in cellular function
(16). As RanBPM does not possess enzymatic activity, it is unclear as to how these
alterations in cellular functions occur.

1.2.3

CTLH complex

When the full-length form of RanBPM was discovered, it was recovered in a 670 kDa
protein complex (4). This complex was later identified as a seven-member complex
termed the CTLH complex as the majority of the complex members featured both a LisH
and a CTLH domain (27). The CTLH complex is comprised of RanBPM along with
RMND5A (required for meiotic nuclear division 5 homolog A), MAEA (macrophage
erythroblast attacher), Muskelin, TWA1 (two hybrid-associated protein 1 with RanBPM),
and ARMc8 (armadillo repeat containing 8) (27, 28) (Figure 1.2). Each member of the
CTLH complex, with the exception of Muskelin, possess a Saccharomyces cerevisiae
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Figure 1.2 Proposed model of the mammalian CTLH complex. The CTLH complex is
comprised of RanBPM (Ran binding protein microtubule organizing center) along with
RMND5A (required for meiotic nuclear division 5 homolog A), MAEA (macrophage
erythroblast attacher), Muskelin, TWA1 (two hybrid-associated protein 1 with RanBPM)
and ARMc8 (armadillo repeat containing 8). WDR26 (WD repeat 26) remains to be
recognized as a CTLH complex member. C17orf39 has not been identified in the
mammalian CTLH complex, however it is proposed to identify specific target substrates
similar to its yeast orthologue GID4 (16). Figure adapted from (16).
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orthologue which compose a large protein complex called the glucose induced
degradation deficient (Gid) complex (6, 29).
The Gid complex is comprised of seven GID proteins that are required for the
proteasome-dependent degradation of fructose 1,6-bisphosphatase (FBPase). The
gluconeogenic enzyme FBPase is rapidly degraded by the Gid complex when S.
cerevisiae cells are switched from a nonfermentable carbon source to glucose (30). There
are in fact two pathways that exist for FBPase degradation, one is dependent on the
ubiquitin-proteasome system, while the other is dependent on the vacuolar proteolysis
system, however only three members of the Gid complex participate in the vacuolar
proteolysis system, one being GID1, the orthologue to RanBPM (30). GID1 functions
primarily as the scaffold to the Gid complex mediating its interactions with the remainder
of the complex through its LisH and CTLH domains (29).
Two other members of the Gid complex, GID2 and GID9, each contain a RING-type
zinc-finger motif, which are indicative of E3 ubiquitin ligase activity. RING domains
interact with and function in conjunction with E2s, ubiquitin conjugating enzymes, to
mediate the ubiquitination of targeted substrates (31, 32). Although GID9 does possess
the RING motif necessary for E3 ubiquitin ligase activity, it did not demonstrate E3
ligase activity in vitro (31). GID2, however, has been shown to polyubiquitinate proteins
in vitro, and mutation to the RING motif was shown to abolish the polyubiquitination of
FBPase (33). The orthologue of GID2, RMND5A, also possesses the RING motif, and
the Xenopus laevis orthologue has been shown to have E3 ubiquitin ligase activity in
vitro, however this activity has not been demonstrated in mammals (34).
Although the Gid complex is a proven E3 ubiquitin ligase complex in yeast, the
mammalian CTLH complex has yet to be shown to exhibit the same activity (6). Other
orthologous E3 ubiquitin complexes exist, such as the symbiosis receptor-like kinase
(SymRK)-interacting E3 ubiquitin ligase (SIE3), a plant-specific E3 ligase that contains
the conserved CTLH, CRA, and RING domains, and has been shown to bind and
ubiquitinate SymRK in vitro and in Lotus japonicas (35). A similar complex has also
been identified to exist in Arabidopsis thaliana (36). Although no data has yet surfaced to
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suggest that the mammalian CTLH complex has E3 ubiquitin ligase activity, there are
data that link members of the CTLH complex to the degradation pathway.
Overexpression of ARMc8, the orthologue of GID5, has been shown to result in the
degradation of a-catenin, and ARMc8 has also been shown to associate with b-catenin
(37). ARMc8A has also been shown to associate with hepatocyte growth factor-regulated
tyrosine kinase substrate (HRS), an essential factor to endosomal and lysosomal
dependent degradation of receptor proteins through endocytosis (38). Muskelin is a key
factor in the internalization of a1 subunit-containing g-aminobutyric acid (GABAA)
receptors in neurons (39). WD repeat domain 26 (WDR26), which is the orthologue to
GID7 and a putative member of the CTLH complex, was also shown to promote the
downregulation of b-catenin (40).
Evidence suggests that members of the CTLH complex have an effect on various protein
levels and functions. However, further insights into these studies are still needed to
understand how the CTLH complex functions, as currently no functional data exist for
the complex as a whole. Only individual subunits have been studied in isolation, with
RanBPM as the most studied subunit.

1.2.4

Role of RanBPM in apoptosis

Substantial evidence suggests that RanBPM has a role in the activation of apoptosis. We
have demonstrated that overexpression of RanBPM results in the activation of caspase-3
leading to cell death by apoptosis in HeLa cells (41). Exposure to ionizing radiation (IR)
causes DNA damage and triggers the activation of the apoptotic pathway primarily
through the mitochondrial pathway regulated by the B cell lymphoma 2 (Bcl-2) protein
family (42). Short hairpin RNA (shRNA) knockdown of RanBPM in the presence of IR
led to reduced mitochondria-associated Bcl-2-associated X protein (Bax), a pro-apoptotic
Bcl-2 family protein, and protein levels of anti-apoptotic proteins Bcl-2 and B cell
lymphoma extra large (Bcl-XL) were significantly increased leading to reduced caspase-3
activation and apoptosis (13, 41). These studies were further substantiated, as RanBPM
overexpression was linked to decreased Bcl-2 protein levels, and increased Bax protein
levels and oligomerization, causing mitochondrial fragmentation and the release of
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cytochrome c ultimately leading to increased apoptotic activity (10, 16). Moreover,
downregulation of RanBPM in gastric cancer cells also proved to effectively render the
cells insensitive to apoptosis-inducing agents (8). Also, the overexpression of RanBPM in
transgenic mice was shown to lead to mitochondrial instability and promoted amyloidbeta (Ab)-induced apoptosis in neuronal cells (43).
Through its protein-protein interaction domains, RanBPM has been shown to interact
with proteins that function to regulate the apoptotic pathway. Interactions between
RanBPM and caspase-processed C-terminal domain of cyclin-dependent kinase 11,
(CDK11p46), a protein involved in apoptotic signaling and a promoter of apoptosis when
ectopically expressed, have been documented (44). Interactions of RanBPM and
homeodomain-interacting protein kinase (HIPK2), an activator of the tumour suppressor
protein p53, and the p75 neurotrophin receptor (p75NTR) have also been shown to occur
(11, 45). RanBPM interacts with the tumour suppressor protein p73, enhancing its proapoptotic activity through inhibition of its ubiquitination and its subsequent degradation
(9), while overexpression of RanBPM causes the upregulation of endogenous p73 mRNA
and protein levels (10). Overall, these studies support that RanBPM has a pro-apoptotic
effect; however, the mechanisms by which RanBPM regulates its interacting proteins still
remain largely unknown.

1.2.5

Role of RanBPM in transcriptional regulation

RanBPM has also been suggested to be involved in the regulation of gene transcription.
Microarray analysis comparing cells stably expressing shRNA for RanBPM to shRNA
controls showed changes in gene expression, influencing transcriptional pathways
associated with development and tumourigenesis (47). Downregulation of RanBPM
revealed over-representation of transcription factor binding sites within the promoters of
the differentially expressed genes, specifically of homeobox A5 (HOXA5), the Forkhead
box (FOX) family of transcription factors, and the High Mobility Group (HMG) family
of transcription factors, suggesting that RanBPM functions in the regulation of the
transcriptome through these factors (47). Furthermore, RanBPM was also shown to
interact with the TATA box binding protein-associated 4 (TAF4) subunit of the
transcription factor II D (TFIID), a transcriptional co-activator for nuclear receptors (48).
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Nuclear receptors thyroid hormone receptor (TR), androgen receptor (AR), and
glucocorticoid receptor (GR), were also shown to interact with RanBPM, enhancing their
transcriptional activity (49-51). Interestingly, proteomics studies have implicated the
CTLH complex as a co-regulator complex for nuclear receptors (52). RanBPM has been
shown to associate with, and negatively regulate, tumour necrosis factor receptorassociated factor 6 (TRAF6) E3 ubiquitin ligase activity causing reduced activation of the
nuclear factor kappa B (NF-kB) signaling pathway (53). Through these studies, it can be
surmised that RanBPM is capable of regulating gene transcription through direct and
indirect modulation of transcription factors.

1.2.6

Role of RanBPM in adhesion, morphology, migration

Associations between RanBPM and proteins responsible for the regulation of adhesion,
morphology and migration have also been reported. Integrins play a significant role in the
regulation of cell survival, proliferation, adhesion and migration, as integrins mediate
cell-to-cell, and cell-to-extracellular matrix interactions, as well as participate in signal
transduction (55). RanBPM has been reported to interact directly with the b2-integrin,
LFA-1, and b1-integrin, with the latter interaction resulting in accelerated endocytosis of
b1-integrin, disrupting cell adhesion and focal adhesion signaling and assembly (43, 54).
Interestingly, some data reveals that RanBPM and Muskelin function to regulate cell
morphology, as knockdown of either proteins resulted in enlarged cell perimeters of
human lung carcinoma cells (56). Additionally, RanBPM was shown to interact with the
PlexinA1 receptor, and through the overexpression of RanBPM cell spreading and
outgrowth were reduced (57).
RanBPM has been shown to negatively regulate cell migration, as it inhibits leukotriene
B4 receptor 2 (BLT2)-mediated motility and its downregulation has been linked to
increased cellular motility in human embryonic kidney (HEK) cells (13, 14). Metastatic
gastric tumours were also shown to harbour low expression levels of RanBPM transcripts
compared to non-metastatic tumours (8). Interestingly, RanBPM has also been shown to
upregulate migration as its interaction with mesenchymal epithelial transition factor
(MET) receptor tyrosine kinase, caused the activation of ERK1/2 thereby increasing
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cellular migration (11). As RanBPM displays divergent roles in cell migration, this may
suggest that RanBPM also plays a role in normal development and tumour suppression.

1.2.7

Role of RanBPM in cancer

Tumorigenesis is viewed as dysregulation of several cellular processes, including, but not
limited to sustained proliferative signals, replicative immortality, tissue invasion, and
evasion of apoptosis and immune destruction (2). As described above, RanBPM has been
suggested to participate in the regulation of these cellular processes (7-15). When
comparing a human gene expression array with RanBPM downregulated cells to normal
cells, 167 genes were identified to have altered expression (47). Of these genes, over onethird were associated with cancer. Previous works in our laboratory have shown RanBPM
to play an inhibitory role in cancer development. RanBPM has been shown to have an
inhibitory effect on histone deacetylase 6 (HDAC6), a cytoplasmic deacetylase necessary
in the formation of aggresomes (58), which, when overexpressed, plays a key role in
cellular transformation and metastasis (59). Our laboratory has also linked RanBPM to
the regulation of the intrinsic apoptotic pathway through inhibition of the ERK1/2
signaling pathway. RanBPM was shown to downregulate C-RAF protein levels and
disrupts the heat shock protein (HSP) 90-C-RAF complex, thereby preventing the
downstream phosphorylation and activation of ERK1/2 (13). RanBPM proved necessary
to the activation of the intrinsic apoptotic pathway, as its knockdown revealed a marked
increase in anti-apoptotic Bcl-2 and Bcl-XL mRNA levels, and decreased mitochondrialassociated Bax (13, 41). Downregulation of RanBPM effectively resulted in the evasion
of apoptosis and the loss of growth factor dependence, as growth serum deprivation
enhanced cell growth and proliferation (13, 41) demonstrating that RanBPM does exhibit
tumour suppressive properties.
Similarly, downregulation of RanBPM in gastric cancer cells has been shown to cause the
reduction in cell adhesion, promoting cell motility and survival (8). Furthermore, distant
metastatic masses were shown to exhibit reduced levels of mRNA and RanBPM protein
levels (8). RanBPM has also been shown to stabilize p73 mRNA and protein levels
during DNA damage, allowing p73 to act as a growth-suppressor and inducing apoptosis
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(9, 10). These findings suggest that RanBPM demonstrates a tumour suppressive role,
and therefore should be regarded as a potential therapeutic of cancer inhibition.

1.3

Mitogen-activated protein kinases

Mitogen-activated protein kinase (MAPK) pathways are an important link between
extracellular signals and eliciting a response from the cell. Currently, there are six
discrete groups of MAPK pathways that have been identified and characterized in
mammalian cells, namely ERK1/2, ERK3/4, ERK5, ERK7/8, p38, and Jun N-terminal
kinase (JNK) (Figure 1.3) (60-63). These pathways are responsible for the strict
regulation of cellular processes essential to the successful survival of cells, providing the
important controls needed in cellular growth, proliferation, differentiation, migration, and
apoptosis (64). Dysregulation of these pathways alter cellular metabolism and result in
developmental defects and cancer development (2).

1.4
1.4.1

C-RAF
ERK1/2 signaling pathway

The ERK1/2 signaling pathway is a topic of great importance as its deregulation has been
documented in approximately one-third of all human cancers and has been linked to
many aspects of the tumour phenotype (64). In this pathway, receptor tyrosine kinases
(RTK) are activated by extracellular ligands, leading to the loading of guanosine
triphosphate (GTP) to rat sarcoma (RAS) GTPase, and the recruitment of RAF kinases
(C-RAF, B-RAF, and A-RAF) to the plasma membrane for activation (Figure 1.4). RAF
then activates mitogen-activated protein kinase kinase (MEK)1/2 by phosphorylation, and
MEK1/2 subsequently phosphorylates ERK1/2, activating numerous cellular processes.
Overexpression of RTK or RTK activating ligands, or activating mutations in rtk, ras, or
b-raf would lead to the constitutive activation of the ERK1/2 signaling pathway (65).
The ERK1/2 pathway possesses the ability to affect a diversity of substrates with
divergent functions: within the nucleus, targeting transcription factors and kinases; in the
cytoplasm, targeting kinases and structural proteins; and at the plasma membrane,
regulating adhesion, cell-to-cell communication and survival (66). Therefore, ERK1/2
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Figure 1.4 ERK1/2 signaling pathway. Extracellular ligands bind to and activate
receptor tyrosine kinases (RTK) causing autophophorylation, which promotes association
of activated RTK to intracellular GRB2 and SOS and the loading of membrane-bound
RAS with GTP. Activated RAS then initiates a cascade of phosphorylation leading to the
activation of RAF, MEK, and ERK, respectively. ERK activation leads to
phosphorylation of targets within the cytoplasm and the nucleus. Specifically, the
activation of transcription factor CREB by activated ERK leads to the transcription of
anti-apoptotic factors Bcl-2 and Bcl-XL.
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signaling is strictly monitored within cells.

1.4.2

RAF family kinases

Three RAF isoforms exist in mammals (Figure 1.5A). C-RAF, the first RAF isoform
identified in 1985 (67), B-RAF, and A-RAF, each share a common structure. Each
isoform consists of three conserved regions (CR), each possessing their own distinct
function necessary to the activity and regulation of the RAF kinases. CR1 contains the
RAS binding domain necessary for RAS binding and subsequent attachment to the
plasma membrane for activation, as well as a secondary RAS binding site, a cysteine-rich
domain, which is required for RAF autoinhibition of the kinase domain (68). CR2
contains activating and inhibitory phosphorylation sites regulating RAS binding and RAF
activation (69). Most importantly, CR3 contains the kinase domain, which is activated
upon phosphorylation of the activating segment, also contained in the CR3 (70). The
regulatory domains CR1 and CR2 are necessary for the regulation of RAF kinase activity,
as upon their removal, constitutive oncogenic activation is achieved (71). As RAF
kinases activate MEK1/2, RAF kinases indirectly activate ERK1/2, therefore RAF
kinases are subjected to extensive regulation.

1.4.3

Activation cycle of C-RAF

Since C-RAF was the first identified RAF isoform, a wealth of knowledge was gathered
about this isoform. However, much focus was later shifted to B-RAF, as several
mutations were documented in this isoform which were determined to lead to
oncogenesis (72). During the inactive state, C-RAF is held in a closed conformation by
the N-terminal regulatory region folding over the C-terminal catalytic domain, with the
14-3-3 dimer stabilizing the conformation by binding phosphorylated S259 (pS259) of
the N-terminal, and pS621 of the C-terminal (73). The activation of C-RAF was studied
intensively (Figure 1.6) however, it is not completely understood. Briefly, pS259 is
dephosphorylated (74) releasing 14-3-3 from the N-terminal and revealing the RAS
binding sites allowing for RAS binding and recruitment to the plasma membrane (75,
76). The activation segment of CR3 is then phosphorylated, specifically S338, to achieve
full kinase activation with RAF homo- or heterodimerization (77), leading to its
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Figure 1.5 Schematics of RAF protein kinases. (A) Human A-, B -, and C-RAF kinases
share a common structure. CR1, CR2, and CR3 are conserved regions between all human
RAF isoforms. The RAS binding domain and catalytic domain are indicated. (B) DN-CRAF corresponds to the catalytic region, or CR3, of C-RAF. Figure adapted from (72).
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Figure 1.6 C-RAF activation cycle. (1) C-RAF is held in a “closed” inactive
conformation by the N-terminal regulatory region (dark purple) folding over the catalytic
C-terminal region (light purple), and is stabilized by the 14-3-3 dimer which binds pS259
of the N-terminal region and pS621 of the C-terminal region. (2) C-RAF progresses to
the “open” inactive state when pS259 is dephosphorylated releasing 14-3-3 from the Nterminal, revealing the RAS binding domain allowing RAS to bind and recruit C-RAF to
the plasma membrane. (3) The CR3 activation segment is phosphorylated, specifically
pS338, to achieve a full “open” active conformation (4) and full kinase activation with
RAF heterodimerization. (5) Deactivation is initiated by the dephosphorylation of pS338,
deactivating the activation segment, and the phosphorylation of S259, allowing 14-3-3 to
rebind the N-terminal and reforming the closed inactive conformation. Figure adapted
from (72).
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subsequent interaction with MEK (78, 79). Deactivation is initiated by the
dephosphorylation of pS338, deactivating the activation segment, and the
phosphorylation of S259, causing 14-3-3 to rebind the N-terminal and reforming the
closed inactive conformation (80). In addition to 14-3-3 regulation, C-RAF has also been
shown to be regulated through direct feedback phosphorylation by ERK1/2, inhibiting
RAS interaction and promoting phosphorylation at inhibitory sites (81).

1.4.4

Activation by heterodimerization

Dimerization is a common feature of kinase activation. Heterodimerization of C-RAF and
B-RAF was demonstrated to occur in multiple cell lines following mitogen activation
(77). C-RAF and B-RAF were found to be cross-linked by the 14-3-3 dimer via their Cterminal domains. ERK1/2 feedback phosphorylation was also found to regulate
heterodimerization by limiting the lifetime of the heterodimer (81).
Approximately 66% of melanomas, and 2% of all human tumours harbour a B-RAF
mutation (82). When B-RAF mutations in cancers were first being identified, V600E
stood out as the most frequent mutation, as well as the strongest stimulating mutation of
B-RAF kinase activity (82). Less frequent mutations exhibited very low or no activity
and still were able to hyperstimulate the ERK1/2 pathway (83). These low-to-no activity
B-RAF kinases mutants were achieving stimulation of the ERK1/2 pathway through
activation of C-RAF by forming heterodimers (77, 84). Regulation of heterodimerization
by RAS is abolished in these cases, and constitutive dimerization occurs leading to
aberrant activation of MEK1/2 (84).

1.4.5

MEK-independent signaling

Only one substrate has been identified and shared across all RAF kinases, that being
MEK1/2. However, B-RAF possesses the strongest activity for MEK1/2 activation,
rendering C-RAF and A-RAF as seemingly unnecessary MEK kinases. C-RAF and ARAF are likely involved in subtler processes independent of MEK (85). Alternative
phosphorylation substrates for C-RAF have been described, such as: adenylyl cyclases
(AC) 2, 5, and 6, AC generates cyclic adenosine monophosphate (cAMP), which
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activates protein kinase A (PKA), a negative regulator of C-RAF (86); retinoblastoma
tumour suppressor protein (Rb), causing inactivation of Rb leading to cell cycle
progression (87); Rho-binding kinase (Rok)-a and myotonic dystrophy protein kinase
(MDPK), both regulators of myosin contractility (88, 89). Through gene knockout mice,
distinct functional roles of RAF kinases were found: A-RAF plays a role in neurological
and intestinal development (90); B-RAF functions in vascular development (91); and
finally C-RAF functions in liver development (92). Each isoform possesses its own
distinct function within cells essential to embryonic development.

1.4.6

C-RAF protein stability

Extensive controls are in place to insure that RAF kinase activity is strictly regulated.
Protein stability and levels within the cell are also important regulators of kinase
signaling pathways. The chaperone protein HSP90 is a well-researched regulator of RAF
kinases. HSP90 is highly conserved and abundant, and is found to associate with, and
chaperone, a wide array of client proteins (93). HSP90 supports the proper folding of
proteins involved in normal cellular activities with the help of more than 20 cochaperones to guide and modulate proteins and their activities (93). The interaction
between HSP90 and RAF is essential to RAF stability and its activity as a signal
transducer within the ERK1/2 signaling pathway (94), as the treatment with
geldanamycin, an inhibitor of HSP90, caused the rapid dissociation of the HSP90-RAF
and RAS-RAF complexes, and caused subsequent reduction in RAF half-life and plasma
membrane association (95).
Although HSP90 is generally regarded to stabilize client proteins, it also plays a role in
their degradation. C-terminus of constitutive heat shock protein (HSC) 70-interacting
protein (CHIP), a highly conserved E3 ubiquintin ligase across species, associates with
the molecular chaperone proteins HSC70-HSP70 and HSP90 causing client proteins to be
ubiquitinated and subsequently degraded via the proteasome (96). C-RAF is one of these
client proteins that is targeted by CHIP for ubiquitination (97), and degradation by the
proteasome (98). X-linked inhibitor of apoptosis proteins (XIAP), another E3 ubiquitin
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ligase, has also been found to interfere with C-RAF stability, promoting ubiquitination
through HSP90-mediated CHIP, independent of its own E3 ligase activity (99).
Interestingly, incidences of CHIP-independent modes of ubiquitination of C-RAF have
also been documented. For successful activation of C-RAF, S621 must be
autophosphorylated in order to allow for correct folding and stability, as pS621 is
necessary to bind 14-3-3 to its C-terminal (73). Without the phosphorylation of S621, CRAF is effectively kinase-dead and is degraded by the proteasome. However, degradation
is not exclusively regulated by CHIP, as siRNA knockdown of CHIP did not yield altered
levels of kinase-dead C-RAF (100). Treatment with the oxidative glucose metabolite
methylglyoxal and abolishing extracellular adhesion has been shown to cause degradation
of C-RAF through the ubiquitin-proteasome system (101, 102). However, the E3
ubiquitin ligase was not identified in either case.
A lesser-known stability regulator of C-RAF is RanBPM, which was identified to bind
the C-RAF kinase domain in a yeast two-hybrid analysis (103). Studies conducted in our
laboratory have shown that RanBPM is capable of regulating C-RAF protein levels. In
shRNA RanBPM cells, RanBPM was co-expressed with a constitutively active form of
C-RAF causing a significant decrease in ectopic C-RAF protein levels, as well as a
decrease in C-RAF-dependent activation of ERK1/2 (13). Endogenous C-RAF protein
levels were also observed to be increased in shRNA RanBPM cells (13). Upon reexpression of RanBPM, the effect was rescued. Co-immunoprecipitation experiments
also confirmed that C-RAF and RanBPM form a complex in mammalian cells, as
endogenous RanBPM forms a complex with the ectopically expressed C-RAF kinase
domain, and that endogenous C-RAF also forms a complex with ectopically expressed
RanBPM (13). Finally, evidence was also provided to show that RanBPM is able to cause
a decrease in HSP90-C-RAF complex formation, and the destabilization of endogenous
C-RAF (13). However, the mechanism underlying this regulation still remains unknown,
as further insights into RanBPM’s regulation of C-RAF protein stability still remain to be
elucidated.
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1.5

Interaction between RanBPM and C-RAF

Unpublished work conducted in our laboratory by Wesley Bérubé-Janzen has made
strides to the elucidation of RanBPM regulation of C-RAF protein stability. Proximity
ligation assay data has visualized the endogenous complex formations of C-RAF with
both RanBPM, and MAEA, the CTLH complex member featuring the degenerate RINGtype zinc-finger domain. Ectopic expression of RanBPM with deletions of its conserved
domains co-expressed with ∆N-C-RAF, a constitutively active construct of C-RAF
featuring only its kinase domain (Figure 1.5B) (79), revealed that the LisH and CTLH
domains, the disordered N-terminal, and the C-terminal CRA domain were required in
the regulation of ∆N-C-RAF protein stability, as their deletion resulted in upregulated
∆N-C-RAF protein levels. However, glutathione-S-transferase (GST) pull down of
ectopically expressed GST-∆N-C-RAF showed loss of interaction with co-expressed
RanBPM only when the CRA domain was deleted. In vitro GST pull down of bacterially
expressed CRA domain demonstrated that the loss of interaction between RanBPM and
∆N-C-RAF was due to the direct interaction mediated by the CRA domain.
Taking all these findings together, we can surmise that through the CRA domain
RanBPM is able to directly interact with C-RAF and promote its interaction with the
remaining components of the mammalian CTLH complex. RanBPM recruits C-RAF to
the CTLH complex through its LisH and CTLH domains imparting regulation on C-RAF
protein stability (Figure 1.7).

1.6

Hypothesis and objectives

The mechanism by which RanBPM imparts regulation on C-RAF, due to its apparent
lack of enzymatic activity, remains unclear. Therefore, it is hypothesized that RanBPM
interacts with and promotes the degradation of C-RAF by targeting C-RAF for
ubiquitination by the mammalian CTLH complex. The work presented herein proposes to
address the following objectives:
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Figure 1.7 Working model of C-RAF protein stability regulation by RanBPM. Three
RanBPM regions, N-terminal (1-102), LisH/CTLH (360-460) and C-terminal CRA (615729) are necessary to regulate C-RAF protein stability, but only the CRA domain is able
to interact with C-RAF. Our working hypothesis is that RanBPM interacts with C-RAF
and recruits it to the CTLH complex associated through interaction with the LisH and
CTLH domains to promote C-RAF ubiquitination and degradation. The role of the Nterminal domain is unclear, but it maybe involved in RanBPM stability and folding (5).
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(1) Determine whether the effect of RanBPM on C-RAF protein stability is dependent
on the proteasome;
(2) Define the region of interaction between RanBPM and C-RAF and investigate the
effects on C-RAF regulation in vitro; and
(3) Investigate the effect on C-RAF regulation by other members of the CTLH
complex.
Over the past several decades it has become increasingly clear that tight regulation of the
ERK1/2 signaling pathway, if through kinase activity or protein stability, is a critical part
to the prevention of unregulated cellular proliferation, differentiation, apoptosis, and
migration. With the identification of RanBPM having associations with the ERK1/2
signaling pathway, a pathway commonly deregulated in cancer, elucidating the tumoursuppressive role of the RanBPM/CTLH complex will provide some relief to the
increasing need to find new MAPK-targeted cancer therapies. As a whole, the research
presented herein will examine the regulatory role that the RanBPM/CTLH complex
imparts on C-RAF protein stability.
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Chapter 2

2

Materials and methods

2.1

Chemicals and reagents

2.1.1

Cell culture

Dubecco’s modified eagle medium (DMEM), L-glutatmine, sodium pyruvate, trypsin,
fetal bovine serum (FBS) and phosphate buffered saline (PBS) were purchased from
Wisent Inc. (St. Bruno, QC, CA). Dimethyl sulfoxide (DMSO), N-carbobenzoxyl-Lleucinyl-L-leucinyl-L-leucinal (MG-132), and G418 sulphate was purchased from
BioShop Inc. (Burlington, ON, CA). JetPRIME® Transfection Reagent was purchased
from PolyPlus Transfection (Illkirch, France).

2.1.2

In vitro assays

Sodium deoxycholate, hydrochloric acid (HCl), Tween-20, sodium dodecyl sulphate
(SDS), sodium chloride (NaCl), Tris-hydroxymethyl amino methane (Tris),
ethylenediaminetetraacetic acid (EDTA), hydroxyethyl piperazineethanesulfonic acid
(HEPES), and potassium chloride (KCl) were purchased from Wisent Inc. (St. Bruno,
QC, CA). Glycerol was purchased from Caledon Laboratory Chemicals Ltd.
(Georgetown, ON, CA). TritonX-100 (TX100), Nonidet P-40 (NP-40), dithiothreitol
(DTT), aprotinin, leupeptin, pepstatin, sodium fluoride (NaF), sodium orthovanadate
(Na3VO4), and pheylmethylsulfonyl fluoride (PMSF) were purchased from BioShop Inc.
(Burlington, ON, CA). Glutathione-agarose beads were purchased from Sigma-Aldrich
(Oakville, ON, CA). Anti-Ubiquitin TUBE (non-selective) Agarose-TUBE 1 by
LifeSensors (Malvern, PA, USA) and N-ethylmalinide (NEM) by Sigma-Aldrich
(Oakville, ON, CA) were provided by Dr. J. Rylett (University of Western Ontario,
London, ON, CA). Polyvinylidene fluoride (PVDF) membranes, Bio-Rad Protein Assay
Dye Reagent Concentrate, and Clarity Western ECL substrate were purchased from BioRad (Mississauga, ON, CA). No Name-Skim Milk Powder was purchased from Loblaw
Companies Ltd. (Brampton, ON, CA).
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2.1.3

Cloning and bacterial expression

KOD Hot Start DNA Polymerase was purchased from EMD Millipore Corporation
(Billerica, MA, USA). Primers were purchased from Integrated DNA Technologies Inc.
(Coralville, IA, USA). Restriction enzymes were purchased from NEW England Biolabs
Inc. (Ipswich, MA, USA). Isopropyl ß-D-1-thiogalactopyranoside (IPTG), Yeast Extract,
and Bio-Tryptone were purchased from BioShop Inc. (Burlington, ON, CA).

2.2
2.2.1

Antibodies
Primary antibodies

C-RAF (C-12; sc133), ß-actin (I-9; sc-1616-R), and GST (B-14; sc138) antibodies were
purchased from Santa Cruz Biotechniology Inc. (Santa Cruz, CA, USA). RanBPM (71001) antibody was purchased from BioAcademia (Suita, Osaka, Japan). Human influenza
hemagglutinin (HA; H9658) antibody was purchased from Sigma-Aldrich (Oakville, ON,
CA). RMND5A (NBP1-92337) antibody was purchased from Novus Biologicals
(Oakville, ON, CA). Table 2.1 summarizes primary antibody dilutions used in this work.

2.2.2

Secondary antibodies

Peroxidase-conjugated AffiniPure Goat anti-Mouse IgG (H+L) was purchased from
Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA), and Blotting Grade
Goat anti-Rabbit IgG (H+L) (Human IgG Adsorbed) Horseradish Peroxidase Conjugate
was purchased from Bio-Rad Laboratories Inc. (Mississauga, ON, CA). Both secondary
antibodies were used at 1:5000 dilutions.

2.3

Cloning and plasmids

pCMV-HA-RanBPM was provided by Dr. Mark Nelson (University of Arizona, Tucson,
AZ, USA) and previously mutagenized as described in (41) to be resistant to shRNA
targeting. pCMV-HA-RanBPM-∆C4 was previously generated as described in (58)
pEBG-GST-∆N-C-RAF was provided by Dr. Zhijun Luo (Boston University, Boston,
MA, USA).
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Table 2.1 Concentrations of primary antibodies used in Western blot analysis.
Antibody

Species

Dilution

C-RAF (C-12)

Rabbit

1:1000

ß-actin (I-19)

Rabbit

1:2000

GST (B-14)

Mouse

1:500

RanBPM

Rabbit

1:2000

HA

Mouse

1:10000

RMND5A

Rabbit

1:300
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pET28a-∆N-C-RAF was generated by Matthew Maitland through the isolation of the ∆NC-RAF fragment in pEBG-GST-∆N-C-RAF using BamHI and NotI, followed by ligation
with T4 DNA ligase into the bacterial expression vector pET28a (EMD Millipore,
Billerica, MA, USA). pGEX-4T-1-GST-C1 was generated by Wesley Bérubé-Janzen
through polymerase chain reaction (PCR) amplification of RanBPM amino acids 649-729
from pCMV-HA-RanBPM. PCR was performed using the KOD Hot Start DNA
Polymerase kit according to manufacturer’s protocol. The PCR amplicon was digested
with BamHI and SalI-HF, and was ligated with T4 DNA ligase into the bacterial
expression vector pGEX-4T-1 (GE Healthcare Life Sciences, Little Chalfont,
Buckinghamshire, UK).
pGEX-4T-1-GST-C1-1, pGEX-4T-1-GST-C1-2, and pGEX-4T-1-GST-C4 were
generated through PCR amplification of RanBPM amino acids 615-669, RanBPM amino
acids 663-729, or RanBPM amino acids 471-729, respectively, from pCMV-HARanBPM. pGEX-4T-1-GST-C4A, pGEX-4T-1-GST-C4B, and pGEX-4T-1-GST-C4C
were generated through PCR amplification of RanBPM amino acids 471-639, RanBPM
amino acids 471-669, or RanBPM amino acids 471-692, respectively, from pGEX-4T-1GST-C4. PCR amplicons were digested with EcoRI-HF and XhoI, and were subsequently
ligated into the bacterial expression vector pGEX-4T-1. pGEX-4T-1-GST-C4D was
generated through PCR amplification of RanBPM amino acids 471-639 and 671-729,
from pGEX-4T-1-GST-C4. Blunt end ligation was performed using T4 Polynucleotide
Kinase. pGEX-4T-1-GST-C4-Q703L T750L, and pGEX-4T-1-GST-C4-R625L E626L
were generated by site-directed mutagenesis of pGEX-4T-1-GST-C4, performed using
KOD Hot Start DNA Polymerase. pCMV-HA-RanBPM-R625L E626L was generated by
site-directed mutagenesis of pCMV-HA-RanBPM, performed using KOD Hot Start DNA
Polymerase. Restriction enzymes were used as directed in the manufacturers’ protocols.

2.4
2.4.1

Cell lines and cell culture
Stable shRNA RanBPM cell lines

HeLa, HCT116, and HEK-293 cells were purchased from the American Type Culture
Collection. Cells were grown in high-glucose DMEM supplemented with 8% FBS, 1%
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sodium pyruvate, 1% L-glutamine, and 4.5 g/L glucose at 37°C and 5% CO2. Cell lines
stably expressing either RanBPM shRNA or non-targeting control shRNA were
previously generated in (13, 41). To maintain stable expression of the shRNA in HeLa,
HCT116, and HEK-293 cells, G418 sulphate was used at 0.35 g/L, 0.35 g/L, and 0.45
g/L, respectively.

2.4.2

CRISPR-Cas9 RMND5A-/- HEK-293 cell line

HEK-293 cells were purchased from the American Type Culture Collection. Cells were
grown in high-glucose DMEM supplemented with 8% FBS, 1% sodium pyruvate, 1% Lglutamine, and 4.5 g/L glucose at 37°C and 5% CO2. Generation of RMND5A -/- HEK293 cells was completed by Schild-Poulter laboratory members Matthew Maitland and
Xu Wang. Briefly, sgRNA (single-guide RNA) was designed against exon 3 of rmnd5a
using www.benchling.com (On-target score = 65.7, Off-target score = 86.0). Top and
bottom oligomers (5’ – CACCGTGGAGCACTTCTTTCGACA – 3’; 5’ –
AAACTGTCGAAAGAAGTGCTCCAC – 3’) were annealed together and ligated with
pSpCas9(BB)-2A-Puro (PX459) V2.0 that was digested with BpiI. Early passage wildtype HEK-293 cells were seeded on 12-well dishes and transfected with 800 ng of
plasmid DNA. Forty-eight hours post-transfection, cells were put under puromycin
selection for seven days. Afterwards, remaining single cells were transferred to a 48-well
dish and expanded. Loss of RMND5A protein was confirmed by Western blot and DNA
mutation was checked by sequencing. The top two predicted off-target sequences were
also checked and revealed no changes.

2.5

Transfections and treatments

JetPRIME Transfection Reagent was used according to manufacturer’s protocols for
transfection of HeLa and HEK-293 cells. The amount of transfection DNA used was
determined by comparative protein expression 24 h post-transfection. pBS-SK (Agilent
Technologies, Santa Clara, CA, USA) was used to supplement transfected DNA to the
minimum DNA amount requirements. Transfected cells were grown at 37°C and 5% CO2
for 24-30 h. MG-132 or DMSO (vehicle) was used at 10 µM for 6-24 h.
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2.6
2.6.1

Cell extracts
Preparation of mammalian cell extracts

HeLa, HCT116, and HEK-293 cells were scraped in cold PBS, and centrifuged for 3
minutes at 8000 rpm. Cell pellets were lysed on ice for 25 minutes in either whole cell
extract buffer (150 mM NaCl, 1 mM EDTA, 50 mM HEPES pH 7.4, 10% glycerol, 0.5%
NP-40, and 0.5% TX100), radioimmunoprecipitation assay (RIPA) buffer (140 mM
NaCl, 1 mM EDTA, 10 mM Tris-HCl pH 8.0, 1% TX100, 0.1% sodium deoxycholate,
and 0.1% SDS), or tandem ubiquitin binding entities (TUBE) cell lysis buffer (0.15 M
NaCl, 1 mM EDTA, 50 mM Tris-HCl pH 7.5, 10% glycerol, 0.5% NP-40 1% TX100, 50
µM MG-132, and 1.25 mg/mL NEM) and supplemented with 10 µg/mL aprotinin, 2
µg/mL leupeptin, 2.5 µg/mL pepstatin, 1 mM DTT, 2 mM NaF, 2 mM Na3VO4, and 0.1
mM PMSF. The cell lysates were clarified at 4 °C for 20 minutes at 13 000 rpm.

2.6.2

Bacterial protein expression and extracts

Bacterial expression plasmids were transformed into Escherichia coli strain BL21-DE3.
Single tranformant colonies were selected and grown in Luria Bertani (LB) liquid culture
media at 37 °C overnight. Cultures were diluted 1:100 into fresh growth media and
grown to an optical density at 600 nm (OD600) of 0.4 – 0.5. Protein expression was
induced using 0.1 mM IPTG and grown overnight at 10 °C. Bacterial cultures were
pelleted at 4 °C for 15 minutes at 4000 rpm. Bacterial cell pellets were lysed in GST
protein lysis buffer (25 mM HEPES pH 7.4, 100 mM KCl, 2 mM EDTA, and 20%
glycerol) supplemented with 0.1% NP-40, 10 µg/mL aprotinin, 2 µg/mL leupeptin, 2.5
µg/mL pepstatin, 1 mM DTT, 2 mM NaF, 2 mM Na3VO4, and 0.1 mM PMSF. Bacterial
lysates were sonicated on ice with the Sonic Dismembrator Model 100 (Thermo Fisher
Scientific Inc.) and clarified at 13 000 rpm for 10 minutes at 4 °C.

2.7

Western blot analyses

Protein samples were resolved by SDS polyacrylamide gel electrophoresis (PAGE) on
variable percentages of acrylamide gels. Gels were transferred to PVDF membranes by
semi-dry transfer at 25V for 25 minutes. Membranes were blocked with 5% skim milk in
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Tris-buffered saline with Tween-20 (TBS-T; 20 mM Tris-HCl pH 8.0, 0.15 M NaCl,
0.05% Tween-20) at room temperature for 1h with agitation. Primary antibodies were
hybridized to membranes either overnight at 4 °C, or 2h at room temperature, with
agitation. Secondary antibodies were hybridized to the membranes at room temperature
for 1h, with agitation. Membranes were developed using Clarity Western ECL Substrate
(Bio-Rad Laboratories Inc.), images were taken using a ChemiDoc MP (Bio-Rad
Laboratories Inc.), and images were analyzed by Image Lab software (Bio-Rad
Laboratories Inc.).

2.8
2.8.1

In vitro assays
Bacterial in vitro GST pull-down assay

GST-tagged bacterial protein extracts were quantified, and approximately 400 µg total
protein was bound to 25 µL of Glutathione-agarose beads. GST-tagged protein samples
were diluted to 200 µL with GST protein lysis buffer and an additional 600 µL of GST
binding buffer (15 mM HEPES pH 7.4, 60 mM KCl, 1.2 mM EDTA, and 12 % glycerol)
was added to the protein sample. Each sample received a final concentration of 0.6% NP40, 0.8% TX100, 10 µg/mL aprotinin, 2 µg/mL leupeptin, 2.5 µg/mL pepstatin, 1 mM
DTT, 2 mM NaF, 2 mM Na3VO4, and 0.1 mM PMSF. Samples were incubated with
Glutathione-agarose beads at 4 °C for 2h with rotation. Beads were subsequently washed
three times with binding buffer supplemented with 0.6% NP-40, 0.8% TX100, 1 mM
DTT, and 0.1 mM PMSF. Each sample was incubated with 600 µg of DN-C-RAF
bacterial extract with a final volume of 800 µL of binding buffer and a final concentration
of 0.6% NP-40, 0.8% TX100, 10 µg/mL aprotinin, 2 µg/mL leupeptin, 2.5 µg/mL
pepstatin, 1 mM DTT, 2 mM NaF, 2 mM Na3VO4, and 0.1 mM PMSF. Samples were
incubated with rotation at 4 °C for 2h. Beads were washed three times with binding
buffer supplemented with 0.6% NP-40, 0.8% TX100, 1 mM DTT, and 0.1 mM PMSF.
Beads were resuspended in SDS loading dye (0.105 g/mL SDS, 0.093 g/mL DTT, 0.35 M
Tris-HCl pH 6.8, and 30% glycerol), boiled for 10 minutes, and centrifuged at 10 000
rpm for 10 seconds. The resulting supernatant was analyzed by Western blot. Relative
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DN-C-RAF protein levels were quantified by normalizing DN-C-RAF to the uppermost
GST-fusion protein band, and comparing values to GST when set to a value of 1.0.

2.9

Statistical analyses

Statistical analyses were performed using GraphPad PRISM (GraphPad Software Inc., La
Jolla, CA, USA). One-way analysis of variance (ANOVA) was performed to compare
multiple groups and two-sample t-test assuming equal variance was performed to
compare pairs of groups. Graphed data are presented as mean ± standard deviation (SD)
and are determined to be significant when p < 0.05.
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Chapter 3

3

Results

3.1

C-RAF is regulated by the proteasome through RanBPM

The Gid complex is the key regulator of the gluconeogenesis pathway in S. cerevisiae,
where it is responsible for the degradation of FBPase through the ubiquitin proteasome
system (30). The Gid complex functions as the E3 ubiquintin ligase that polyubiquinates
FBPase targeting it for degradation through the proteasome. Components of the
mammalian CTLH complex share a striking resemblance to their Gid complex
counterparts, and exhibit evolutionary conservation in a vast variety of species (6),
suggesting that the mammalian complex may exhibit similar activity. GID1, the
orthologue to RanBPM (30), is a central component of the E3 ubiquitin ligase and
functions primarily as the scaffold to the Gid complex mediating its interactions with the
remainder of the complex through its LisH and CTLH domains (29). Deletion of the
SPRY, the LisH, or the CTLH domain resulted in impaired FBPase degradation owing to
lack of ubiquitination suggesting that any alterations to GID1 affects E3 ubiquitin ligase
activity of the complex (29).
Previous studies showed that C-RAF protein levels are increased in RanBPM shRNA
cells, suggesting that RanBPM may function to target C-RAF for degradation (13). To
determine whether RanBPM regulates C-RAF protein stability through the proteasomal
degradation pathway, similar to the regulation of FBPase by GID1 through the GID
complex, RanBPM-targeting or non-targeting control shRNA HeLa, HEK-293, and
HCT116 cells previously described in (13, 41), were used to assess C-RAF protein levels
in conditions of proteasomal impairment in order to determine whether the RanBPM loss
of function would affect C-RAF degradation. All cell lines were treated with either 10
µM of the proteasome inhibitor, MG132, or with the vehicle, DMSO. MG132 inhibits the
proteasome, preventing the degradation of ubiquitin-conjugated proteins, thus resulting in
their accumulation within cells. However, cells harbouring impaired E3 ligase activity
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because of the loss of RanBPM would lack this accumulation. Cells were harvested 24 h
post-treatment and analyzed by Western blot.
HeLa, HEK-293, and HCT116 cells expressing RanBPM shRNA showed minimal
accumulation of C-RAF protein levels during proteasomal inhibition, whereas control
shRNA cells exhibited a 1.85 ± 0.55 – fold (SD), 1.59 ± 0.19 – fold (SD), and 2.36 ± 0.50
– fold (SD) increase accumulation of C-RAF, respectively, when compared to their
respective vehicle-treated controls (Figure 3.1). This suggests that the downregulation of
RanBPM impairs proteasome-dependent degradation of C-RAF.

3.2

The CRA domain of RanBPM is highly conserved
throughout evolutionary time

The C-terminal CRA domain was shown to function as a protein-protein interaction
domain and was predicted to have six a-helices, reminiscent of the death domain
superfamily (18). Previous co-immunoprecipitation and in vitro pull down assays
performed in our laboratory showed that RanBPM and C-RAF complex formation is
dependent on the RanBPM CRA domain suggesting that the CRA domain functions to
mediate an interaction between RanBPM and C-RAF (13, 104). In order to map the
region of interaction between the CRA domain and C-RAF, sequence alignment of CRA
domain homologues was performed (Figure 3.2) using the multiple sequence alignment
online server MUSCLE (MUltiple Sequence Comparison by Log-Expectation) (105108). Through multiple sequence alignment of RanBPM CRA domain homologous
sequences, residues that have been conserved through evolution would be inferred as
important to the function of the CRA domain as a protein interaction surface. However,
identifying which residue may be important for this interaction proved difficult, as
sequence alignment of the RanBPM CRA domain revealed that 77.4% of residues were
fully conserved, 11.3% held conservation of strongly similar properties, 1.7% of residues
had conservation of weakly similar properties, and 9.6% were not conserved. Therefore,
alternative measures must be taken to define the region of the CRA domain responsible
for C-RAF binding.
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Figure 3.1 C-RAF is regulated by the proteasome through RanBPM. Stable nontargeting shRNA control and shRNA RanBPM cells were treated with 10µM MG132 or
DMSO, as vehicle, for 24h. RIPA buffered whole cell extracts of (A) HeLa, (B) HEK293, and (C) HCT116 were analyzed by Western blot with RanBPM, C-RAF and β-actin
antibodies to detect RanBPM, C-RAF and β-actin proteins, respectively. C-RAF protein
levels were normalized to β-actin levels. Quantifications of relative C-RAF protein levels
for (D) HeLa, (E) HEK-293, and (F) HCT116 are shown with error bars indicating SD
(n=4). A two-sample t-test, assuming equal variance, was used to determine significance.
* p<0.05; ** p<0.01; ns not significant.
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Figure 3.2 Sequence alignment of the conserved RanBPM CRA domain. RanBPM
CRA domain sequences of Homo sapiens, Mus musculus, Xenopus laevis and Danio
rerio, were aligned using the multiple sequence alignment online server MUSCLE (105108) * fully conserved; : conservation of strongly similar properties; . conservation of
weakly similar properties.
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3.3

The CRA domain of RanBPM interacts directly with ∆N-CRAF

As an alternative to single point mutations, we thought to design partial deletions of the
CRA domain to disrupt or remove the site of interaction with C-RAF. As there is no
crystal structure of RanBPM or the CRA domain currently available, a predicted tertiary
structure was elucidated by the RAPTORX online server (Figure 3.3A) (16, 109). The
predicted tertiary structure corroborated the previous assumption that the CRA domain
has a high propensity for a-helices, with 6 a-helices spanning the entirety of the domain
(Figure 3.3B). We, therefore, generated various deletion mutants of the RanBPM CRA
domain to evaluate the effect of these deletions on the association of C-RAF. Deletions
were guided by the predicted tertiary structure and data previously generated by Wesley
Bérubé-Janzen which showed amino acids 649 – 729 of RanBPM, denoted C1, bound
directly to DN-C-RAF, a constitutively active construct of C-RAF featuring only its
kinase domain, and inversely that their deletion significantly decreased this interaction
(104).
To assess interaction between the CRA domain and DN-C-RAF, deletion mutants of the
CRA domain were cloned into the bacterial expression vector pGEX-4T-1, downstream
of GST and GST pull down assays were performed (Figure 3.4). Initial CRA domain
constructs were modelled after C1 and guided by the predicted tertiary structure. The
CRA domain is mapped to amino acids 615 – 729 of RanBPM, therefore only a portion
of the CRA domain is represented by C1, which contains helices IV, V and VI, and a
small portion of helix III. We, therefore, derived two GST-fusion CRA constructs which
featured amino acids 615 – 669 spanning helices I, II, and III, denoted C1-1, and amino
acids 663 – 729 containing helices IV, V, and VI, denoted C1-2. These constructs were
purified using glutathione-agarose beads and incubated with crude E. coli cell lysate of
DN-C-RAF. The GST-fusion constructs were pulled down and analyzed by Western blot
to evaluate relative levels of bound DN-C-RAF protein. All GST pull down assays were
normalized to the negative control, GST, and compared to the positive DN-C-RAF
binding control, GST-C4, which contains amino acids 471 – 729 of RanBPM, and
therefore includes sequences C-terminal to the CTLH domain, namely the CRA domain.

36

A

B

I

II

III

V
IV

VI

Figure 3.3 Predicted tertiary structure of RanBPM. (A) Full-length RanBPM with the
omission of the unstructured N-terminal region, amino acids 1-153 and (B) an expanded
image of the RanBPM CRA domain with a-helices labelled I through VI are shown.
SPRY, LisH, CTLH, and CRA domains are shown in light-blue, light-pink, violet, and
hot-pink, respectively. Linker regions are shown in dark blue, and unstructured regions
are omitted. The structure prediction of RanBPM was elucidated by RAPTORX software
(109) and adapted from (16).
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GST-C1 displayed significant interaction with DN-C-RAF, although quantifications
showed reduced binding compared to GST-C4, by 2.6 ± 0.6 –fold (SD), which confirmed
previous findings (Figure 3.5A; Bérubé-Janzen, unpublished). Constructs GST-C1-1 and
GST-C1-2 were constructed to examine the binding of helices I – III and helices IV – VI
to DN-C-RAF, respectively. However, both constructs appeared to lack protein stability
in vitro, as they bound less DN-C-RAF than that of the negative control. Both constructs
displayed a drastic decrease in DN-C-RAF binding by 4.6 ± 0.5 –fold (SD), and 4.5 ± 0.5
–fold (SD), respectively.
To increase protein stability, CRA domain constructs were expanded to include the
portion of RanBPM C-terminal to the CTLH domain, in other terms, modelling the
constructs after C4 to include RanBPM sequences N-terminal to the CRA domain (Figure
3.4). Similar to the strategy used for the two previous constructs, CRA deletion mutations
were guided by the predicted tertiary structure. We derived an additional four GST-fusion
CRA constructs: C4A which spans amino acids 471 – 639 and helices I and II; C4B
contains amino acids 471 – 669 and helices I – III; C4C is comprised of amino acids 471
– 692 and helices I – IV; and finally, C4D which includes amino acids 471 – 639 and 671
– 729, and helices I – II and IV – VI. DN-C-RAF binding was again tested by GST pull
down assay and the mutants’ binding to DN-C-RAF was quantified and compared to that
of GST-C4: GST-C4A showed decreased binding by 3.6 ± 0.5 –fold (SD); GST-C4B
decreased by 3.1 ± 0.6 –fold (SD); GST-C4C decreased by 2.7 ± 0.5 –fold (SD); and
GST-C4D decreased by 2.1 ± 0.6 –fold (SD) (Figure 3.5B).
Overall, these data suggest that each helix of the CRA domain has a role to play in the
binding of DN-C-RAF. As more helices were deleted from the CRA domain, less binding
of DN-C-RAF was observed. However, two portions of the CRA domain seemed worth
investigating, helices I and II, and helices V and VI, demonstrated by C1 and C4C,
respectively. Deletion of helices I and II, and helices V and VI resulted in a sharp
decrease in DN-C-RAF binding with the least amount of the CRA domain deleted.
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Figure 3.4 Schematics and predicted structures of the C-terminal CRA domain
mutants of RanBPM. C-terminal CRA domain mutants were cloned into the bacterial
expression vector pGEX-4T-1, downstream of GST.
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Figure 3.5 The CRA domain of RanBPM interacts directly with ∆N-C-RAF. GST
pull-down assays were performed using GST, GST-C4, (A) GST-C1, GST-C1-1 and
GST-C1-2; (B) GST-C4A, GST-C4B, GST-C4C, and GST-C4D; and (C) GST-C4Q703L T705L, denoted GST-C4-QT, and GST-C4-R625L E626L, denoted GST-C4-RE,
E. coli extracts and crude ΔN-C-RAF E. coli extracts. Pull-downs were analyzed by
Western blot with C-RAF and GST antibodies to detect ΔN-C-RAF and GST-fusion
proteins, respectively. (D) Relative DN-C-RAF protein levels were quantified by
normalizing DN-C-RAF to the uppermost GST-fusion protein band, and comparing
values to GST when set to a value of 1. Quantifications are shown with error bars
indicating SD (n = 3-5). Statistical analysis was performed using ANOVA.
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Therefore, point mutations were designed to target the center of helices I and II, or helix
V, in efforts to disrupt the helical structures within the CRA domain and the binding
interface between CRA and DN-C-RAF. Site-directed mutagenesis was used to create C4
with point mutations R625L and E626L within helix I and II, denoted C4 – R625L
E626L, or with point mutations Q703L and T705L within helix V, denoted C4 – Q703L
T705L. DN-C-RAF binding was tested by GST pull down assay: GST-C4- R625L E626L
showed a significant loss in DN-C-RAF binding with a 3.4 ± 0.5 –fold (SD) decrease,
whereas GST-C4- Q703L T705L did not disrupt the interaction, showing only a slight
decrease in DN-C-RAF binding (Figure 3.5C). These results suggest that the mutation
R625L E626L made to helix I and II of the CRA domain was sufficient to disrupt the
interaction between the CRA domain and DN-C-RAF in vitro.

3.4

The CRA domain of RanBPM is necessary for the regulation
of ΔN-C-RAF in human cells

Previous studies conducted in our laboratory have shown that both endogenous C-RAF
and ectopically expressed DN-C-RAF are downregulated by RanBPM, as the
downregulation of RanBPM resulted in an increase of both endogenous and ectopic CRAF protein levels and the re-expression of RanBPM rescued these effects (13). To
validate our in vitro binding data (Figure 3.5D), mutant RanBPM CRA domains were
cloned into the mammalian expression vector pCMV downstream of the HA-tag (Figure
3.6), and co-transfected with pEBG-GST-DN-C-RAF into HeLa RanBPM shRNA cells.
We chose to evaluate the regulation of ectopically expressed DN-C-RAF as the effects of
RanBPM regulation are more prominent compared to the regulation of endogenous CRAF (13). pCMV-HA-RanBPM- ΔC1 containing a deletion of amino acids 649 – 729 of
RanBPM, and pCMV-HA-RanBPM- R625L E626L were chosen to investigate their
effect on DN-C-RAF regulation. pCMV, pCMV-HA-RanBPM-WT, the full-length form
of RanBPM, or pCMV-HA-RanBPM-ΔC4 containing a deletion of amino acids 471 –
729 of RanBPM, were also transfected into HeLa shRNA cells to serve as a transfection
control, a positive control for DN-C-RAF regulation, or a negative control for DN-C-RAF
regulation, respectively. Given that our in vitro binding data showed a significant
reduction in DN-C-RAF binding of constructs C1 and C4 – R625L E626L, we expected
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Figure 3.6 Schematics of RanBPM and mutants used in transfection. WT, DC4,
R625L E262L, and DC1 RanBPM mutant constructs were cloned into the pCMV-HA
mammalian expression vector.
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to see an equivalent loss in DN-C-RAF regulation ex vivo. These mutations should
theoretically cause impaired targeting of DN-C-RAF to the CTLH complex resulting in
decreased ubiquitination and subsequent degradation of DN-C-RAF.
HA-RanBPM-ΔC1 showed significant loss of DN-C-RAF regulation, resulting in a 2.9 ±
0.3 –fold increase (SD) in DN-C-RAF protein levels compared to HA-RanBPM-WT
confirming our in vitro binding data and previous results reported by Wesley BérubéJanzen (Figure 3.7A, C; unpublished). However, evaluation of the R625L E626L point
mutations in this system did not confirm the in vitro binding data (Figure 3.7B, C) as the
ectopic expression of HA-RanBPM- R625L E626L maintained the regulation of DN-CRAF protein levels to a level comparable to HA-RanBPM-WT.

3.5

RMND5A regulates endogenous C-RAF protein levels

The Gid complex functions as an E3 ubiquitin ligase to regulate key enzymes of the
gluconeogenesis pathway through polyubiquitination and subsequent degradation (30).
GID2, the orthologue to the mammalian RMND5A, is essential for glucose-induced
ubiquitination of FBPase (30). GID2’s E3 ligase activity is conferred by its degenerate
RING-type zinc-finger domain as its activity to polyubiquintinate proteins has been
shown to occur in vitro, and mutation to its RING domain abolishes FBPase
polyubiquitination and degradation in vivo (33). The mammalian orthologue of GID2,
RMND5A, also possess the RING motif and it is hypothesized to function as the E3
ligase to the CTLH complex (6), although this activity has yet to be confirmed.
RMND5A was knocked out of HEK-293 cells via CRISPR-Cas9 (RMND5A -/-) in order
to investigate its role in endogenous C-RAF protein regulation. This knockout would
theoretically cause impaired degradation of C-RAF, as the removal of RMND5A from
the CTLH complex would abolish the presumed E3 ubiquitin ligase activity of the
complex. Western blot analysis of RMND5A -/- cell extracts showed a 6.7 ± 1.4 –fold
(SD) increase of endogenous C-RAF protein levels compared to wild-type HEK-293
(Figure 3.8). Endogenous C-RAF regulation was rescued by ectopically expressing HARMND5A in RMND5A -/- cells for 24 h, decreasing endogenous C-RAF
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Figure 3.7 The CRA domain of RanBPM is necessary for the regulation of ΔN-CRAF in cells. HeLa RanBPM shRNA cells were transfected with pEBG-GST-ΔN-CRAF and either pCMV empty vector, pCMV-HA-RanBPM-ΔC4, (A) pCMV-HARanBPM-ΔC1, or (B) pCMV-HA-RanBPM-R625L E626L, and whole cell extracts were
prepared 24 h post-transfection and analyzed by Western blot. HA, C-RAF and β-actin
antibodies were used to detect HA-RanBPM constructs, DN-C-RAF and β-actin proteins,
respectively. (C) Relative DN-C-RAF protein levels were quantified by normalizing DNC-RAF to β-actin, and comparing values to HA-WT when set to a value of 1. Statistical
analysis was performed with ANOVA. Error bars indicate SD (n=4).
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Figure 3.8 RMND5A regulates endogenous C-RAF protein levels. (A) RIPA-buffered
whole cell extracts of wild-type HEK-293 cells and CRISPR-Cas9 RMND5A-/- HEK-293
cells were prepared and analyzed by Western blot. pCGN-HA-RMND5A was transfected
into RMND5A-/- HEK-293 cells to rescue the effect on endogenous C-RAF protein levels.
C-RAF, HA, RMND5A, and β-actin antibodies were used to detect endogenous C-RAF,
exogenous HA-RMND5A, endogenous RMND5A, and β-actin, respectively. (B)
Relative endogenous C-RAF protein levels were quantified by normalizing C-RAF to βactin, and comparing values to wild-type HEK-293 when set to a value of 1.
Quantifications are shown with error bars indicating SD (n=4). A two-sample t-test,
assuming equal variance, was used to determine significance. * p < 0.05
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protein levels by 4.9 ± 1.6 –fold (SD) compared to mock-transfected RMND5A -/- cells.
These results demonstrate that endogenous C-RAF protein levels are affected by
RMND5A expression, and suggest that RMND5A plays a key role in the regulation of
endogenous C-RAF protein levels.

47

Chapter 4

4

Discussion

4.1

Summary of findings

The aim of this study was to characterize the regulation of C-RAF stability by RanBPM
and the CTLH complex. We hypothesized that RanBPM interacts with and promotes the
degradation of C-RAF by targeting it for ubiquitination by the CTLH complex.
Specifically, we aimed to determine whether the effect of RanBPM on C-RAF protein
stability is dependent on the proteasome, define the region of interaction between
RanBPM and ∆N-C-RAF, and to investigate the effect on C-RAF regulation by other
members of the CTLH complex. In summary, we found that RanBPM regulates C-RAF
degradation through the proteasome, and the entire CRA domain of RanBPM is
necessary for direct interaction with ∆N-C-RAF and for its effective downregulation in
human cells. Finally, the CTLH complex member RMND5A regulates endogenous CRAF protein levels further implicating the CTLH complex in RanBPM-mediated
regulation of C-RAF stability.

4.2

RanBPM and the CTLH complex promote the regulation of
C-RAF protein levels in a proteasome-dependent manner

In addition to regulation through phosphorylation, C-RAF has been shown to be
regulated through protein-protein interactions (69, 110, 111). Interactions with RAS and
14-3-3 proteins, homo- and heterodimerization, and association with chaperone proteins
HSP90 and HSP/HSC70, all participate in the regulation of C-RAF stability and activity
(112). Although C-RAF has been studied for more than 30 years, very little information
has come to light on C-RAF degradation. Current literature proposes C-RAF degradation
to occur in a proteasome-dependent manner (112). XIAP and the HSP90 inhibitor
geldanamycin were both shown to be responsible for the direct destabilization of the
HSP90-C-RAF complex resulting in enhanced proteasome-dependent degradation of CRAF (98, 99).
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In Chapter 3.1, we investigated whether the loss of RanBPM function would affect CRAF degradation under conditions of proteasomal impairment. In wild-type cells
expressing RanBPM, treatment with the proteasome inhibitor MG132 was shown to
augment C-RAF protein levels. In contrast, cells with the stable downregulation of
RanBPM did not show accumulation of C-RAF. The downregulation of RanBPM likely
resulted in a reduction in C-RAF ubiquitination which prevented its accumulation in
proteasome-impaired conditions. This would strongly suggest that RanBPM functions to
mediate the recruitment of a protein complex to C-RAF, causing the destabilization of
HSP90 and C-RAF, leading to the ubiquitination of C-RAF and its degradation by the
proteasome.
Previous experiments were performed in our laboratory to identify the E3 ligase
responsible for RanBPM-enhanced degradation of C-RAF. CHIP was investigated as a
possible candidate, as previous studies have shown C-RAF to be a CHIP substrate (97,
99). However, CHIP was not identified in complex with C-RAF and RanBPM (113),
suggesting CHIP may not be the E3 ligase responsible for RanBPM-mediated C-RAF
ubiquitination. As RanBPM is the orthologue to the yeast GID1 protein (6), an essential
component to the E3 ligase Gid complex (29), we hypothesized that the mammalian
CTLH complex fills this mechanistic void. RanBPM would function to recruit C-RAF to
the CTLH complex to promote C-RAF degradation. RanBPM is likely to function
independently of CHIP, as there have been other modes of C-RAF ubiquitination
documented. For example, siRNA knockdown of CHIP did not prevent the degradation
of the S621A C-RAF mutant by the proteasome (100). Treatment with the oxidative
glucose metabolite methylglyoxal, abolishing extracellular adhesion, and the use of the
chemotherapy regimen GOLF (gemcitabine, oxaliplatin, leucovrin, and 5-Fluorouracil)
have also been shown to cause degradation of C-RAF through the ubiquitin-proteasome
system independently of CHIP (101, 102, 114). This leads us to believe that RanBPM
interaction with C-RAF may serve to recruit the CTLH complex, thereby destabilizing
the HSP90-C-RAF complex and promoting C-RAF ubiquitination by the CTLH complex,
and enhancing proteasomal degradation of C-RAF. Although there is currently no
evidence that demonstrates E3 ubiquitin ligase activity of the CTLH complex as a whole,
there is plenty of evidence to suggest that members of the CTLH complex are involved in
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the process of ubiquitination and degradation. For example, WDR26 was demonstrated to
promote the downregulation of b-catenin (40), and ARMc8a has been shown to promote
the association of HRS with ubiquitinated proteins, as well as promote the degradation of
a-catenin when overexpressed (37, 38). Also, the CTLH complex was shown to bind
Axin, a scaffold protein which has a role in the regulation of the ubiquitination and
degradation of b-catenin (115). RanBPM has also been shown to be involved in the
process of ubiquitination. For example, RanBPM has been shown to interact with
transforming growth factor beta receptor type I (TbRI), reducing auto-ubiquination of
TRAF6, an E3 ubiquitin ligase (7). However, there still remains research to be done in
order to implicate RanBPM and the CTLH complex, in the process of ubiquitination.
Previous data collected by Wesley Bérubé-Janzen demonstrated that endogenous C-RAF
and MAEA form a complex in situ (104), implicating an interaction between C-RAF and
the CTLH complex. In Chapter 3.4 we showed that the CTLH complex member
RMND5A also regulates endogenous C-RAF protein levels. CRISPR-Cas9 knockout of
RMND5A in HEK-293 cells (RMND5A-/-) showed a drastic increase in endogenous CRAF protein levels, while re-expression of RMND5A reversed the effect. As RMND5A
is the mammalian orthologue to GID2, the Gid complex member responsible for the E3
ligase activity of the complex (27, 28), these observations further support the role of the
CTLH complex as the E3 ligase responsible for RanBPM-mediated C-RAF degradation.

4.3

The evolutionarily conserved CRA domain of RanBPM is
required for direct interaction with, and regulation of, C-RAF

Numerous studies have shown that RanBPM is a promiscuous protein, interacting with
over 75 proteins (16). Only a handful of studies have implicated specific conserved
domains of RanBPM to be responsible for its interaction. The RanBPM SPRY domain
appears to mediate the majority of these interactions. For example, the RanBPM SPRY
domain has been shown to associate with CDK11p46 (44), ubiquitin carboxyl-terminal
hydrolase 11 (USP11) (116), steroid receptors AR and GR (51), MET (11) BLT2 (14),
and many others (16). The LisH and CTLH domains have also been shown to mediate the
interaction between RanBPM and HDAC6 (58), RanBP10 (117), and Alzheimer’s
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disease related proteins amyloid precursor protein (APP), low-density lipoprotein
receptor-related protein (LRP), and b-site APP-cleaving enzyme 1 (BACE1) (118).
However, protein-protein interactions involving the RanBPM CRA domain are limited to
the fragile X mental retardation protein (FMRP) (18) the only protein reported as an
interacting protein through this domain, and with C-RAF which was identified by
previous MSc student Wesley Bérubé-Janzen (104).
In Chapter 3.2, we showed that the RanBPM CRA domain is highly conserved between
four homologous sequences. Additionally, in Chapter 3.3 we showed that any alteration
made to the CRA domain structure resulted in a significant decrease in DN-C-RAF
binding in vitro, while in Chapter 3.4 we showed a loss in regulation of DN-C-RAF by
RanBPM when the CRA domain was impaired. Overall, this suggests that the RanBPM
CRA domain sequence and its structure are essential to the proper binding, and regulation
of C-RAF by RanBPM.
In Chapter 3.3, in vitro deletion mutants C1 and C4C showed a significant decrease in
DN-C-RAF binding. This suggests that helices I, II, V and VI are important to the
interaction between the CRA domain and DN-C-RAF. Site-directed mutagenesis was
used to disrupt the secondary structure of helices I and II or helix V in hopes of
disrupting the interaction between the CRA domain and C-RAF. In vitro binding data
suggested that the disruption of helices I and II was effective in disrupting this
interaction. However, ectopically expressed RanBPM – R625L E626L retained its
regulation of DN-C-RAF comparable to wild-type RanBPM suggesting that the point
mutation did not disrupt the interaction between the CRA domain and DN-C-RAF ex
vivo.
In vitro binding of the RanBPM CRA domain to DN-C-RAF was studied in isolation,
whereas the regulation of DN-C-RAF by RanBPM – R625L E626L was studied ex vivo
allowing the RanBPM mutant to interact with the CTLH complex. As the CRA domain is
not required for the association of RanBPM to the CTLH complex (29) it is possible that
the CRA domain structure was stabilized by the formation of the CTLH complex thereby
preserving the binding interface between the CRA domain and C-RAF, while in vitro, the
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CRA domain structure may have been compromised when studied in isolation. This
stabilizing effect can also be observed in the formation of the Gid complex, as the
stability of the members of the Gid complex is dependent on their interactions within the
complex (29). The R625L E626L mutation of the CRA domain may have also enhanced
the affinity of the bond between the CRA domain and C-RAF. Work by Haling and
colleagues determined that the molecular basis of the interaction between the B-RAF
kinase domain and MEK-1 was the hydrophobic interface that functions to shield the
flexible activation segments of both proteins within the B-RAF activation site (119).
With the R625L E626L mutation in the CRA domain, it is possible that this mutation had
increased the hydrophobicity of the CRA domain, thereby increasing C-RAF binding
affinity. In the future, it will be important to determine whether reducing the
hydrophobicity of the CRA domain results in reduced affinity for C-RAF, thus reducing
its regulation in human cells.
How RanBPM is able to interact with C-RAF and mediate its downregulation is
important to determining how this interaction impacts ERK1/2 signaling. Our laboratory
has already demonstrated that without RanBPM-mediated downregulation of C-RAF,
phosphorylation of MEK1/2 and ERK1/2 is increased, subsequently causing the
increased transcription of anti-apoptosis regulators Bcl-2 and Bcl-XL (13). However, this
is only a fraction of what occurs upon dysregulation of the ERK1/2 signaling pathway. A
recent phospho-proteomic study has implicated the ERK1/2 signaling pathway in over
2500 phosphorylation events with approximately one-quarter of these events as a result of
direct ERK1/2 phosphorylation (120). Efforts thus far have focused on determining the
effects of activated ERK1/2 on the regulation of transcription factors as transcription
factors govern essential cellular processes. For example, transcription factors ELK1 and
c-FOS were identified as substrates of activated ERK1/2 (66, 121), and as a result of their
increased expression due to ERK1/2 activation, cell-cycle regulatory proteins are
expressed enabling the progression of the cell through Gap 1 phase of the cell cycle
(122). These phosphorylation events resulting from deregulated ERK1/2 activation lead
to unrestrained differentiation and proliferation, and deregulated motility and apoptosis,
ultimately leading to tumourigenesis (2, 66, 72). Therefore, the regulation of C-RAF
mediated by RanBPM and the CTLH complex presents as a significant topic of research.
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4.4

Limitations of the study and future work

Although there are currently two proteins to have been identified to interact with the
RanBPM CRA domain, it is improbable that all the RanBPM CRA domain interacting
proteins have been identified. The kinase domains of A-RAF and B-RAF share a strong
resemblance to that of the C-RAF kinase domain, with a high value of 71.8% sequence
identity (Figure 4.1), therefore it is probable that the RanBPM-mediated and RMND5Amediated degradation of C-RAF presented in this study is not exclusive to C-RAF.
Preliminary studies conducted in our laboratory have shown that RMND5A-/- cells also
contain higher protein levels of A-RAF and B-RAF (123). This suggests that RMND5A,
the CTLH complex member assumed to possess E3 ligase activity, functions to regulate
A-RAF and B-RAF in addition to C-RAF. Future studies should focus on implicating the
remaining CTLH complex members by investigating the effects of knocking out each
member of the complex on the regulation of human RAF kinases.
As each RAF isoform has distinct functions within cells, RanBPM and the CTLH
complex may function to mediate A-RAF function in the developmental stages of
neurological and intestinal growth, and apoptosis during epithelial differentiation (90,
124). More importantly, RanBPM and the CTLH complex may be further implicated in
the regulation of the ERK1/2 signaling pathway and the prevention of its dysregulation as
the B-RAF isoform is commonly mutated in a significant number of cancers (72), with
higher incidence of B-RAF mutations in melanoma and thyroid cancers (125, 126).
Although the data presented in Chapter 3.4 does strongly implicate RMND5A in the
regulation of C-RAF protein levels, it still remains unclear as to whether RMND5A does
so through E3 ubiquitin ligase activity. During this study, several attempts were made to
show changes in the ubiquitination state of C-RAF. However, this proved to be difficult.
Previous to the establishment of the RMND5A-/- HEK-293 cell line, HeLa cells
expressing RanBPM-targeting shRNA and non-targeting shRNA were used to investigate
C-RAF ubiquitination. Early attempts were focused on showing ectopically expressed
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Figure 4.1 Sequence alignment of RAF protein kinase domains. Sequences of human
RAF protein kinase domains were aligned using the multiple sequence alignment online
server MUSCLE (105-108). * fully conserved; : conservation of strongly similar
properties; . conservation of weakly similar properties.
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HA-ubiquitination of endogenous C-RAF, where antibodies targeting HA or C-RAF were
used to immunoprecipitate HA-ubiquitin-tagged endogenous C-RAF under proteasome
and deubiquitinase inhibition. However, the antibodies were unable to precipitate
significant levels of C-RAF protein (data not shown). As RanBPM has been shown to
preferentially bind to the active form of C-RAF (13), it would be improbable that we
would be able to discern a change in endogenous C-RAF ubiquitination as both active
and inactive forms of C-RAF exist within human cells.
Next, we investigated the ubiquitination of ectopically expressed DN-C-RAF, however
we were again unsuccessful. GST-DN-C-RAF and HA-ubiquitin were co-expressed in
HeLa RanBPM-targeting shRNA and non-targeting shRNA cells under conditions of
proteasome and deubiquitinase inhibition. GST pull-down revealed that DN-C-RAF was
degraded, suggesting a low protein half-life of DN-C-RAF when bound to glutathioneagarose beads. Also, no HA-ubiquitin-tagged DN-C-RAF was detected within the sample
(data not shown).
Finally, we attempted to show endogenous ubiquitination of ectopically expressed DN-CRAF in HeLa RanBPM-targeting shRNA and non-targeting shRNA cells, and HEK-293
wild-type and RMND5A-/- cells by tandem ubiquitin binding entities (TUBE) assay.
TUBE functions by preferentially isolating polyubiquitinated proteins and provides
protection from deubiquitination and degradation from the proteasome. DN-C-RAF was
ectopically expressed in each cell line and treated with proteasome and deubiquitinase
inhibitors. The resultant cellular lysate was incubated with TUBE. No visible change in
amounts of ubiquitinated DN-C-RAF protein was observed by Western blot analysis in
either HeLa or HEK-293 cell types (data not shown).
A recurring issue has been observed with the analysis of C-RAF ubiquitination. Previous
studies have been able to show polyubiquitination of human C-RAF (97-102, 114, 127),
however showing a decrease or increase to the level of endogenous ubiquitination of CRAF due to the loss or the addition of an E3 ligase in human cells, respectively, has not
been documented. The TUBE assay does present itself as a potentially valuable tool to
show variations in C-RAF ubiquitination, however further optimization is still required.
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Efforts should be concurrently focused on demonstrating E3 ligase activity of human
RMND5A and demonstrating C-RAF as a RMND5A E3 substrate, thereby implicating
the CTLH complex as an E3 ubiquitin ligase complex.

4.5

Conclusion

Overall, this study aimed to investigate the regulation of C-RAF stability by RanBPM
and the CTLH complex. Although this study has added to our knowledge of RanBPMmediated regulation of C-RAF and further implicates the CTLH complex in this process,
the exact function of both still remains unclear. Further exploration into the function of
RanBPM and the CTLH complex is essential to understanding the role of this protein
complex in the regulation of ERK1/2 signaling, and the prevention of human
tumourigenesis.
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